Panel Discussion: PPILT meets the patent cliff — Can Goa’s pricing model handle a biologics wave?

Panelists in this video:
• Dr Subrata Chakraborty, Founder, INOPHAR Consulting & Training (MODERATOR)
• Mr Nilesh Hegu, Site Head – Goa II, Cipla
• Dr Pankaj Kumar, VP/Head R&D & Director, Wallace Pharmaceuticals
• Mr Uttam Kadam, Sterile Head, Zydus Lifesciences, Goa
• Dr Prabhat Dessai, Associate Professor & Assistant Director, Placement & Corporate Relations Cell, Parul University, Goa
• Prof (Dr) G Shaber Ali, Professor Of Law, Former Principal, V M Salgaocar College of Law

Key Highlights:
[1] PPILT combines procurement and negotiated pricing, rather than functioning as a standalone pricing policy.

[2] Confidential pricing remains a key challenge, requiring a balance between industry interests and public transparency.

[3] PPILT could attract biologics manufacturing and technology transfer to Goa.

[4] Goa’s next growth phase will require specialised talent, with academia currently struggling to match industry demand.

[5] Complex generics require a fundamentally different R&D approach, with higher investment and advanced analytical capabilities.

[6] Industry 4.0 and AI are reshaping pharma manufacturing, but stronger academia-industry collaboration will be essential.